Literature DB >> 2436773

Evaluation of fludarabine phosphate in renal cell carcinoma: a Southwest Oncology Group Study.

L Balducci, B Blumenstein, D D Von Hoff, M Davis, H E Hynes, R M Bukowski, E D Crawford.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2436773

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  4 in total

1.  Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study.

Authors:  D H Shevrin; T E Lad; L J Kilton; M A Cobleigh; R R Blough; L L Weidner; N J Vogelzang
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

Review 2.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

3.  Ocular toxicity of fludarabine: a purine analog.

Authors:  Xiaoyan Ding; Alexandra A Herzlich; Rachel Bishop; Jingsheng Tuo; Chi-Chao Chan
Journal:  Expert Rev Ophthalmol       Date:  2008-02

Review 4.  Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.

Authors:  G Rodriguez
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.